IL87776A - Antiretroviral preparations containing (2, 3-Didhaoxycitidine for the prevention of SDIA) - Google Patents
Antiretroviral preparations containing (2, 3-Didhaoxycitidine for the prevention of SDIA)Info
- Publication number
- IL87776A IL87776A IL8777688A IL8777688A IL87776A IL 87776 A IL87776 A IL 87776A IL 8777688 A IL8777688 A IL 8777688A IL 8777688 A IL8777688 A IL 8777688A IL 87776 A IL87776 A IL 87776A
- Authority
- IL
- Israel
- Prior art keywords
- dideoxycytidine
- tablet
- pharmaceutical compositions
- ingredients
- aids
- Prior art date
Links
- WREGKURFCTUGRC-POYBYMJQSA-N Zalcitabine Chemical compound O=C1N=C(N)C=CN1[C@@H]1O[C@H](CO)CC1 WREGKURFCTUGRC-POYBYMJQSA-N 0.000 title claims description 9
- 239000008194 pharmaceutical composition Substances 0.000 title claims description 7
- 230000000798 anti-retroviral effect Effects 0.000 title abstract description 3
- 239000000203 mixture Substances 0.000 claims abstract description 16
- 229960000523 zalcitabine Drugs 0.000 claims description 13
- 208000030507 AIDS Diseases 0.000 claims description 8
- 241001430294 unidentified retrovirus Species 0.000 claims description 4
- 238000001990 intravenous administration Methods 0.000 claims description 2
- 239000004480 active ingredient Substances 0.000 abstract description 11
- 239000003826 tablet Substances 0.000 description 17
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 16
- 239000004615 ingredient Substances 0.000 description 13
- 238000009472 formulation Methods 0.000 description 12
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 8
- 235000019359 magnesium stearate Nutrition 0.000 description 8
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 8
- 239000008108 microcrystalline cellulose Substances 0.000 description 8
- 229940016286 microcrystalline cellulose Drugs 0.000 description 8
- 229920002785 Croscarmellose sodium Polymers 0.000 description 7
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 7
- 229960001681 croscarmellose sodium Drugs 0.000 description 7
- 235000010947 crosslinked sodium carboxy methyl cellulose Nutrition 0.000 description 7
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 6
- 239000008101 lactose Substances 0.000 description 6
- 239000008279 sol Substances 0.000 description 6
- 239000000243 solution Substances 0.000 description 6
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 6
- 229920003084 Avicel® PH-102 Polymers 0.000 description 5
- 150000001875 compounds Chemical class 0.000 description 5
- 239000007788 liquid Substances 0.000 description 5
- 238000000034 method Methods 0.000 description 5
- 239000000843 powder Substances 0.000 description 5
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 4
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 4
- UQSXHKLRYXJYBZ-UHFFFAOYSA-N Iron oxide Chemical compound [Fe]=O UQSXHKLRYXJYBZ-UHFFFAOYSA-N 0.000 description 4
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
- 230000000840 anti-viral effect Effects 0.000 description 4
- 239000000969 carrier Substances 0.000 description 4
- GUBGYTABKSRVRQ-DCSYEGIMSA-N Beta-Lactose Chemical compound OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-DCSYEGIMSA-N 0.000 description 3
- 210000004027 cell Anatomy 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 239000000796 flavoring agent Substances 0.000 description 3
- 235000019634 flavors Nutrition 0.000 description 3
- 238000002347 injection Methods 0.000 description 3
- 239000007924 injection Substances 0.000 description 3
- 239000000725 suspension Substances 0.000 description 3
- 239000008215 water for injection Substances 0.000 description 3
- SGHZXLIDFTYFHQ-UHFFFAOYSA-L Brilliant Blue Chemical compound [Na+].[Na+].C=1C=C(C(=C2C=CC(C=C2)=[N+](CC)CC=2C=C(C=CC=2)S([O-])(=O)=O)C=2C(=CC=CC=2)S([O-])(=O)=O)C=CC=1N(CC)CC1=CC=CC(S([O-])(=O)=O)=C1 SGHZXLIDFTYFHQ-UHFFFAOYSA-L 0.000 description 2
- 235000010643 Leucaena leucocephala Nutrition 0.000 description 2
- 240000007472 Leucaena leucocephala Species 0.000 description 2
- 235000011034 Rubus glaucus Nutrition 0.000 description 2
- 244000235659 Rubus idaeus Species 0.000 description 2
- 235000009122 Rubus idaeus Nutrition 0.000 description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
- 229930006000 Sucrose Natural products 0.000 description 2
- 235000012745 brilliant blue FCF Nutrition 0.000 description 2
- 239000000839 emulsion Substances 0.000 description 2
- 238000004108 freeze drying Methods 0.000 description 2
- 235000011187 glycerol Nutrition 0.000 description 2
- 239000008187 granular material Substances 0.000 description 2
- LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 2
- BQJCRHHNABKAKU-KBQPJGBKSA-N morphine Chemical compound O([C@H]1[C@H](C=C[C@H]23)O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4O BQJCRHHNABKAKU-KBQPJGBKSA-N 0.000 description 2
- 239000002777 nucleoside Substances 0.000 description 2
- QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 239000005720 sucrose Substances 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 238000011282 treatment Methods 0.000 description 2
- 230000003612 virological effect Effects 0.000 description 2
- WVXRAFOPTSTNLL-NKWVEPMBSA-N 2',3'-dideoxyadenosine Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@H]1CC[C@@H](CO)O1 WVXRAFOPTSTNLL-NKWVEPMBSA-N 0.000 description 1
- WREGKURFCTUGRC-UHFFFAOYSA-N 4-Amino-1-[5-(hydroxymethyl)oxolan-2-yl]pyrimidin-2-one Chemical compound O=C1N=C(N)C=CN1C1OC(CO)CC1 WREGKURFCTUGRC-UHFFFAOYSA-N 0.000 description 1
- 241000416162 Astragalus gummifer Species 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 241000725303 Human immunodeficiency virus Species 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- 229920001615 Tragacanth Polymers 0.000 description 1
- 208000036142 Viral infection Diseases 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 239000003708 ampul Substances 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 239000003443 antiviral agent Substances 0.000 description 1
- 230000031018 biological processes and functions Effects 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000001185 bone marrow Anatomy 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 239000008364 bulk solution Substances 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 230000000973 chemotherapeutic effect Effects 0.000 description 1
- 229940110456 cocoa butter Drugs 0.000 description 1
- 235000019868 cocoa butter Nutrition 0.000 description 1
- 229940075614 colloidal silicon dioxide Drugs 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 239000002537 cosmetic Substances 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- LQJVOKWHGUAUHK-UHFFFAOYSA-L disodium 5-amino-4-hydroxy-3-phenyldiazenylnaphthalene-2,7-disulfonate Chemical compound [Na+].[Na+].OC1=C2C(N)=CC(S([O-])(=O)=O)=CC2=CC(S([O-])(=O)=O)=C1N=NC1=CC=CC=C1 LQJVOKWHGUAUHK-UHFFFAOYSA-L 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- SZVJSHCCFOBDDC-UHFFFAOYSA-N ferrosoferric oxide Chemical compound O=[Fe]O[Fe]O[Fe]=O SZVJSHCCFOBDDC-UHFFFAOYSA-N 0.000 description 1
- 239000006260 foam Substances 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 230000002519 immonomodulatory effect Effects 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 230000000266 injurious effect Effects 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- YOBAEOGBNPPUQV-UHFFFAOYSA-N iron;trihydrate Chemical compound O.O.O.[Fe].[Fe] YOBAEOGBNPPUQV-UHFFFAOYSA-N 0.000 description 1
- 239000007937 lozenge Substances 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- 239000008176 lyophilized powder Substances 0.000 description 1
- 229940057948 magnesium stearate Drugs 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 238000002483 medication Methods 0.000 description 1
- 235000010270 methyl p-hydroxybenzoate Nutrition 0.000 description 1
- 239000004292 methyl p-hydroxybenzoate Substances 0.000 description 1
- 229960002216 methylparaben Drugs 0.000 description 1
- 229960005181 morphine Drugs 0.000 description 1
- 239000002324 mouth wash Substances 0.000 description 1
- 230000002981 neuropathic effect Effects 0.000 description 1
- 235000020925 non fasting Nutrition 0.000 description 1
- 150000003833 nucleoside derivatives Chemical class 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 235000015205 orange juice Nutrition 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 239000006072 paste Substances 0.000 description 1
- 235000010603 pastilles Nutrition 0.000 description 1
- 208000033808 peripheral neuropathy Diseases 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 238000011321 prophylaxis Methods 0.000 description 1
- 235000010232 propyl p-hydroxybenzoate Nutrition 0.000 description 1
- 239000004405 propyl p-hydroxybenzoate Substances 0.000 description 1
- 229960003415 propylparaben Drugs 0.000 description 1
- 239000008213 purified water Substances 0.000 description 1
- 230000010076 replication Effects 0.000 description 1
- YGSDEFSMJLZEOE-UHFFFAOYSA-M salicylate Chemical compound OC1=CC=CC=C1C([O-])=O YGSDEFSMJLZEOE-UHFFFAOYSA-M 0.000 description 1
- 229960001860 salicylate Drugs 0.000 description 1
- 239000001509 sodium citrate Substances 0.000 description 1
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
- 239000001488 sodium phosphate Substances 0.000 description 1
- 229910000162 sodium phosphate Inorganic materials 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 238000013268 sustained release Methods 0.000 description 1
- 239000012730 sustained-release form Substances 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 239000007916 tablet composition Substances 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- 238000011200 topical administration Methods 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 239000000196 tragacanth Substances 0.000 description 1
- 235000010487 tragacanth Nutrition 0.000 description 1
- 229940116362 tragacanth Drugs 0.000 description 1
- RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 description 1
- 230000009385 viral infection Effects 0.000 description 1
- 230000007484 viral process Effects 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Virology (AREA)
- Molecular Biology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Tropical Medicine & Parasitology (AREA)
- AIDS & HIV (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Saccharide Compounds (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US9825587A | 1987-09-18 | 1987-09-18 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| IL87776A true IL87776A (en) | 1994-01-25 |
Family
ID=22268410
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL8777688A IL87776A (en) | 1987-09-18 | 1988-09-16 | Antiretroviral preparations containing (2, 3-Didhaoxycitidine for the prevention of SDIA) |
Country Status (13)
| Country | Link |
|---|---|
| EP (1) | EP0307914B1 (de) |
| JP (1) | JP2648329B2 (de) |
| KR (1) | KR960014991B1 (de) |
| AT (1) | ATE78693T1 (de) |
| AU (1) | AU616427B2 (de) |
| CA (1) | CA1334166C (de) |
| DE (1) | DE3873232T2 (de) |
| HK (1) | HK99593A (de) |
| HU (1) | HUT47856A (de) |
| IE (1) | IE62191B1 (de) |
| IL (1) | IL87776A (de) |
| PH (1) | PH24796A (de) |
| ZA (1) | ZA886107B (de) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4978655A (en) * | 1986-12-17 | 1990-12-18 | Yale University | Use of 3'-deoxythymidin-2'-ene (3'deoxy-2',3'-didehydrothymidine) in treating patients infected with retroviruses |
| US5276019A (en) * | 1987-03-25 | 1994-01-04 | The United States Of America As Represented By The Department Of Health And Human Services | Inhibitors for replication of retroviruses and for the expression of oncogene products |
| EP0355245A1 (de) * | 1988-08-26 | 1990-02-28 | Michel Vandevelde | Anwendung von Inhibitoren der reversen Transcriptase von Retroviren |
| EP0472595A4 (en) * | 1989-05-15 | 1992-07-08 | Us Commerce | Method of treatment of hepatitis |
| JPH04501857A (ja) * | 1989-05-15 | 1992-04-02 | アメリカ合衆国 | 肝炎の治療方法 |
| ES2060373T3 (es) * | 1990-04-19 | 1994-11-16 | Previsan Sa | Derivados azoicos, compuestos farmaceuticos y desinfectantes que los contienen y su utilizacion contra el sida. |
| US5585367A (en) * | 1990-04-19 | 1996-12-17 | Previsan S.A. | Method of treating humans and animals infected with viruses of the retrovirus group |
| JP2593409Y2 (ja) * | 1992-12-02 | 1999-04-12 | エスエムケイ株式会社 | キーボードスイッチ |
| DE4419256A1 (de) * | 1994-06-01 | 1995-12-07 | Rau Freiherr Von Nagell Helmut | Verwendung von intravenös applizierbarem Eisen zur Therapie von Tumorerkrankungen und/oder Infektionskrankheiten |
| DE4421159C1 (de) * | 1994-06-20 | 1995-08-24 | Thomas Bruns | Verwendung von Eisen(III)-oxid (Fe¶2¶O¶3¶) bei Immunschwäche |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE3689976T2 (de) * | 1985-05-15 | 1995-03-16 | Wellcome Found | Therapeutische Nucleoside und deren Herstellung. |
| GB8512542D0 (en) * | 1985-05-17 | 1985-06-19 | Atomic Energy Authority Uk | Improved cutting edges |
| WO1987001284A1 (en) * | 1985-08-26 | 1987-03-12 | United States Of America, Represented By The Unite | Inhibition of in vitro infectivity and cytopathic effect of htlv-iii/lav by 2',3'-dideoxynosine, 2',3'-dideoxyguanosine, or 2',3'-dideoxyadenosine |
| JPS62501777A (ja) * | 1985-08-26 | 1987-07-16 | アメリカ合衆国 | ２′，３′―ジデオキシシチジンを含有する抗ｈｔｌｖ―３／ｌａｖ剤 |
-
1988
- 1988-03-16 JP JP63060647A patent/JP2648329B2/ja not_active Expired - Lifetime
- 1988-08-17 ZA ZA886107A patent/ZA886107B/xx unknown
- 1988-09-15 CA CA000577518A patent/CA1334166C/en not_active Expired - Fee Related
- 1988-09-15 EP EP88115146A patent/EP0307914B1/de not_active Expired - Lifetime
- 1988-09-15 KR KR1019880011892A patent/KR960014991B1/ko not_active Expired - Fee Related
- 1988-09-15 DE DE8888115146T patent/DE3873232T2/de not_active Expired - Lifetime
- 1988-09-15 AT AT88115146T patent/ATE78693T1/de not_active IP Right Cessation
- 1988-09-15 PH PH37547A patent/PH24796A/en unknown
- 1988-09-16 HU HU884867A patent/HUT47856A/hu unknown
- 1988-09-16 AU AU22345/88A patent/AU616427B2/en not_active Expired
- 1988-09-16 IE IE283688A patent/IE62191B1/en not_active IP Right Cessation
- 1988-09-16 IL IL8777688A patent/IL87776A/en active Protection Beyond IP Right Term
-
1993
- 1993-09-23 HK HK995/93A patent/HK99593A/en not_active IP Right Cessation
Also Published As
| Publication number | Publication date |
|---|---|
| PH24796A (en) | 1990-10-30 |
| HUT47856A (en) | 1989-04-28 |
| ZA886107B (en) | 1989-04-26 |
| IE882836L (en) | 1989-03-18 |
| EP0307914A2 (de) | 1989-03-22 |
| HK99593A (en) | 1993-09-30 |
| AU616427B2 (en) | 1991-10-31 |
| KR960014991B1 (ko) | 1996-10-23 |
| DE3873232D1 (de) | 1992-09-03 |
| AU2234588A (en) | 1989-03-23 |
| JPS6483020A (en) | 1989-03-28 |
| CA1334166C (en) | 1995-01-31 |
| EP0307914B1 (de) | 1992-07-29 |
| IE62191B1 (en) | 1994-12-28 |
| KR890004705A (ko) | 1989-05-09 |
| EP0307914A3 (en) | 1989-08-09 |
| ATE78693T1 (de) | 1992-08-15 |
| JP2648329B2 (ja) | 1997-08-27 |
| DE3873232T2 (de) | 1992-12-03 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US4879277A (en) | Antiviral compositions and methods | |
| KR960011772B1 (ko) | 개선된 디데옥시 퓨린 뉴클레오사이드 경구 투여 제제 | |
| JPH0215523B2 (de) | ||
| EP0307914B1 (de) | Ein Dideoxynukleosid enthaltendes Arzneimittel | |
| US4415590A (en) | Herpes treatment | |
| US4438138A (en) | Reduction of cholesterol with meta-chloro α-t-butylaminopropiophenone | |
| US4888343A (en) | Pharmaceutical compositions for relief of dysmenorrhea and/or premenstrual syndrome and process | |
| EP0629400B1 (de) | Idebenone-haltige Zusammensetzungen zur Behandlung von M. Alzheimer | |
| US5028595A (en) | Method for preventing AIDS in a subject or treating a subject infected with the AIDS virus | |
| EP1218011B1 (de) | Gallium komplexe von 3-hydroxy-4-pyronen zur behandlung von durch intrazelluläre prokaryoten, dns- und retro-viren verursachten infektionen | |
| KR0143410B1 (ko) | B형 비루스성 간염치료용 제약학적 조성물 | |
| SK129999A3 (en) | Pharmaceutical composition, preparation process and use thereof | |
| EP0362162B1 (de) | Pharmazeutische Zubereitung, die Zidovudin und Inosiplex oder Bestandteile davon enthält, für die Behandlung von AIDS-verwandten Syndromen | |
| JPH06500537A (ja) | アテローム硬化症の治療のためのアリールヒドロキシ尿素化合物の使用 | |
| JPH0761946B2 (ja) | エイズ・ウイルス増殖抑制剤 | |
| US5955498A (en) | Agent for prophylaxis and therapy of diseases | |
| JP2007297412A (ja) | ヒト・ヘルペスウイルス−８の治療に対するペンシクロビルの使用 | |
| Luby | Antiviral chemotherapy | |
| EP0338404A1 (de) | Verwendung von Megestrol-Acetat zur Herstellung einer pharmazeutischen Zusammensetzung zur Behandlung von Aids-verbundener Kachexie | |
| US4971977A (en) | Anti-viral pharmaceutical compositions | |
| Machida et al. | Effect of 1-beta-D-arabinofuranosyl-E-5-(2-bromovinyl) uracil (brovavir) on experimental infections in mice with herpes simplex virus type 1 strains of different degrees of virulence | |
| Collignon et al. | Neurological toxicity associated with vidarabine (adenine arabinoside) therapy | |
| JPH06199674A (ja) | 日和見感染症の治療・予防に関する医薬 | |
| CN1084622C (zh) | 药物 | |
| JPS61236725A (ja) | 脳浮腫抑制剤 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| KB | Patent renewed | ||
| KB | Patent renewed | ||
| KB | Patent renewed | ||
| EXTN | Extension order renewed |